Skip to main content
European Commission logo print header

Prostate disorders : procurement of biomarkers and pharmaceuticals

Objective

we will procure biomarkers and pharmaceuticals for prostate disorders. About 1 in 4 men over 55 have lower urinary tract symptoms due to benign prostatic hyperplasia, and 1 in 10 a lifetime risk of prostate cancer. Prostate disorders are a growing major socio-economic challenge because of our ageing population. We are clinicians, scientists and industrialists with complementary expertise and proven ability to collaborate. We will use prostate samples that are clinically well-defined and proprietary (DATAS) and established (suppression subtractive hybridisation, proteomics) approaches to identify changes in gene expression. We will show in clinical and model systems that these changes are important for prostate pathogenesis, and develop diagnostic/prognostics biomarkers and therapeutics for the painful and debilitating disorders of the prostate.

Call for proposal

Data not available
æ

Coordinator

CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
Address
Rue rené descartes 15
67084 Strasbourg
France

See on map

EU contribution
No data

Participants (6)